Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Nerinetide - Arbor Vita Corporation/NoNO

Drug Profile

Nerinetide - Arbor Vita Corporation/NoNO

Alternative Names: NA-1; Tat-NR2B9c

Latest Information Update: 22 Sep 2023

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Arbor Vita Corporation; NoNO
  • Developer Arbor Vita Corporation; NoNO; University of Calgary
  • Class Peptides; Vascular disorder therapies
  • Mechanism of Action PDZ domain inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Phase III Stroke
  • Phase I Traumatic brain injuries
  • Preclinical Alzheimer's disease; Anxiety disorders; Epilepsy; Ischaemia; Pain
  • No development reported Subarachnoid haemorrhage

Most Recent Events

  • 11 Sep 2023 Nerinetide is still in phase III trials for Stroke in USA, Australia, Germany (NCT04462536)
  • 31 Aug 2023 NoNo in collaboration with University of Calgary completes a phase III trial for Stroke in USA, Australia, Canada, Germany, Italy, Netherlands, Norway, Singapore, Switzerland (IV) (NCT04462536)
  • 27 Mar 2023 NoNO completes the phase III FRONTIER trial for Stoke in Canada (IV) (NCT02315443)
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top